[Cancer Immunotherapy Using Gene Modification Technology]

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Recent immunological discoveries and gene modification technologies are driving novel cancer immunotherapies.
• Chimeric antigen receptor (CAR)-T cell therapy, a gene-modified cell therapy, has been approved by the FDA.
• Solid tumors remain a challenge for conventional CAR-T cell therapy.

Purpose of the Study:

• To review the advancements and potential of gene-modified cell therapies in cancer treatment.
• To highlight emerging strategies like 4th generation CAR-T cells and T cell receptor (TCR)-T cells targeting neoantigens.
• To discuss the potential of other immune cells and the development of personalized and universal cell therapies.

Main Methods:

• Review of current research in immunology and gene modification technologies for cancer therapy.
• Analysis of novel CAR-T cell generations and T cell receptor (TCR)-T cell approaches.
• Exploration of alternative immune effector cells and allogeneic "off-the-shelf" cell therapy.

Main Results:

• 4th generation CAR-T cells demonstrate potential in eradicating solid tumors.
• T cell receptor (TCR)-T cells targeting neoantigens offer a new avenue for cancer treatment.
• Other lymphocyte subsets (NK, iNKT, gd T cells) are being explored as gene-modified effector cells.

Conclusions:

• Gene-modified cell therapies, including advanced CAR-T and TCR-T cells, hold significant promise for cancer immunotherapy.
• Personalized medicine and universal "off-the-shelf" technologies are critical for the future advancement and accessibility of these treatments.